Hitachi: Proton Therapy Provider Chosen for UW Health Eastpark Medical Center

MADISON, WI, Jul 27, 2022 – (JCN Newswire via SEAPRWire.com) – UW Health has selected Hitachi, Ltd. (TSE:6501, “Hitachi”) to provide the infrastructure to support proton therapy at UW Health Eastpark Medical Center. Proton therapy equipment combined with Hitachi’s 360° rotating gantry and Leo’s upright system Hitachi will provide equipment and technology to support UW […]

Shonan Kamakura Advanced Medical Center Begins Treatment with Hitachi’s First Dedicated Compact Proton Therapy System

TOKYO, Feb 2, 2022 – (JCN Newswire via SEAPRWire.com) – Hitachi, Ltd. (TSE: 6501) has announced that “Shonan Kamakura Advanced Medical Center” at Shonan Kamakura General Hospital of Tokushukai Medical Group, where Hitachi’s compact proton therapy system (hereafter, “the system”) has been installed, has commenced treatment with the system on 31 January 2022. This is […]

Hitachi Selected by the University of Tsukuba for its Second Proton Therapy System as a PFI Project

TOKYO, Nov 22, 2021 – (JCN Newswire via SEAPRWire.com) – Hitachi, Ltd. (TSE: 6501) announced today that it has been selected by the University of Tsukuba to provide Hitachi’s proton therapy solution including its design, manufacturing, construction, maintenance and operation as a PFI (Private Finance Initiative) project*. The parties have signed the contract on September […]

Topelia Australia launches US$25M Series A call for COVID-19 ATT Ziverdox

SYDNEY, Oct 14, 2021 – (ACN Newswire via SEAPRWire.com) – Topelia Australia, a biotech company established to commercialise a novel ATT treatment for Australians in quarantine, has launched an investment program designed to keep the invention Australian owned – while rolling out treatment to the world. Prof Thomas Borody – Topelia announces US$25 mil Series […]

Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401)

TOKYO, Jun 24, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of Alzheimer’s disease (AD). Breakthrough Therapy designation is an FDA program […]

Ivermectin Triple Therapy Protocol for COVID-19 Released to Australian GPs for Infected Elderly and Frontline Workers

SYDNEY, Aug 19, 2020 – (ACN Newswire) – Triple therapy specialist Professor Thomas Borody, famous for curing peptic ulcers using a triple antibiotic therapy saving millions of lives, today released the COVID-19 treatment protocol to Australian GPs, who can legally prescribe it to their COVID-19 positive patients, and can also prescribe it as a preventative […]